ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine
"This patent provides important protection for ICT-107, and adds to
The ICT-107 patent was issued to
Forward-Looking Statements for
This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including the risk that ICT-107 can be further successfully developed or commercialized, the status of the current data and whether further analyses or later studies may confirm the PFS results to date, the potential for funding and the initiation and design of phase III trials and possibility of successful results from such studies. Additional risks and uncertainties are described in IMUC's most recently filed quarterly report on Form 10-Q and annual report on Form 10-K. Except as permitted by law, IMUC undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. In this press release, you can identify forward-looking statements by terms such as "may," "will," "should," "could," "would," "expect," "plan," "anticipate," "believe," "estimate," "project," "predict," "potential," "future," "intend," "certain," and similar expressions intended to identify forward-looking statements.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/immunocellular-therapeutics-announces-issuance-of-key-patent-for-ict-107-cancer-vaccine-300010883.html
News Provided by Acquire Media